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Zebrafish is an established model for the study of vertebrate development, and is especially amenable for investigating
hematopoiesis, where there is strong conservation of key lineages, genes, and developmental processes with humans.
Over recent years, zebrafish has been increasingly utilized as a model for a range of human hematopoietic diseases,
including malignancies. This review provides an overview of zebrafish hematopoiesis and describes its application as a
model of leukemia and other hematopoietic disorders.
Keywords: Zebrafish, Leukemia, Myeloproliferative disorder, Myelodysplastic syndromeIntroduction
Zebrafish represents an alternative model for the study
of vertebrate development and its perturbation, with
powerful molecular, cellular, and genetic approaches
available. This model has proven particularly useful for the
study of hematopoiesis and its disruption, with zebrafish
possessing all major blood cell types, which are generated
by similar developmental pathways [1,2]. There is also
strong conservation of transcription factors, signaling
components, and functional proteins [3-7]. This review
overviews zebrafish hematopoiesis and describes the
application of this organism to the study of leukemia
and other hematopoietic proliferative disorders.
Review
Zebrafish hematopoiesis
Like other vertebrates, zebrafish undergoes distinct waves
of hematopoiesis [8]. At 10 h post fertilization (hpf), the
ventral lateral mesoderm gives rise to hemangioblasts,
bipotential cells expressing both hematopoietic (scl, lmo2,
gata2), and vascular (flk1, fli1) transcription factors [9],
which become further specified into both hematopoietic
and endothelial cells [10].
Primitive hematopoiesis is initiated from these cells at
two locations, the anterior lateral mesoderm (ALM) and
the posterior lateral mesoderm (PLM) that later forms* Correspondence: award@deakin.edu.au
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unless otherwise stated.the intermediate cellular mass (ICM) (Figure 1) [11,12].
In the ALM, hemangioblasts differentiate into spi1+
myeloid precursors around 12 hpf, which migrate rostrally
and then laterally across the yolk sac [13,14] and begin to
express genes encoding cell surface colony-stimulating
factor receptors csf1r [15] and csf3r [16]. These mature into
distinct myeloid populations with differential expression of
the genes for the myeloid-specific actin binding protein
l-plastin [15] and the granulocytic enzyme myeloperoxidase
(mpo) [17]. In the PLM, gata1+ erythroid precursors are
generated at 12 hpf [18]. These commence expression of
the erythropoietin receptor (epor) gene and differentiate
into primitive erythrocytes expressing erythroid-specific
genes including those encoding key enzymes (such as alas2
and carbonic anhydrase) and globins (such as hbbe3) [19],
which enter circulation around 24 hpf and persist until 4
dpf [1]. Around 24 hpf, a transient ‘intermediate’ wave of
hematopoiesis occurs in the posterior blood island
(PBI). Here, bipotent erythromyeloid progenitors (EMP)
differentiate into gata1+ erythroid and spi1+ myeloid cells
(Figure 1) [13,20].
Definitive hematopoietic stem cells (HSC) are initially
formed at around 33 hpf by budding from the hemogenic
endothelium on the ventral wall of the dorsal aorta, equiva-
lent to the aorta-gonad-mesonephros (AGM) in mammals
[21,22]. From 48 hpf, a subset of the c-myb+ runx1+ HSCs
expressing cd44 migrate from the dorsal aorta to the
caudal hematopoietic tissue (CHT), equivalent to the fetal
liver in mammals [10]. Erythropoiesis commences at 3.5
dpf in the CHT as identified by expression of gata1 andhis is an Open Access article distributed under the terms of the Creative
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Figure 1 Zebrafish hematopoiesis and its key regulators. Schematic representation of hematopoiesis in zebrafish. The primitive wave
commences in two locations, the anterior lateral mesoderm (ALM) (orange), which gives rise to primitive monocytes, and the intermediate
cellular mass (ICM) (violet), which generates mostly primitive erythrocytes before 24 hpf. A transient ‘intermediate’ wave occurs in the posterior
blood island (PBI) where both erythrocytes and heterophils are formed (grey). Definitive hematopoietic stem cells (HSCs) are initially formed by budding
from the hemogenic endothelium on the ventral wall of dorsal aorta (blue). A subset of these HSCs migrate to the caudal hematopoietic tissue (CHT)
(yellow) to produce several cell lineages, and also the thymus (purple), where T lymphocyte production occurs. Finally, HSCs seed the developing kidney
(green), the final site of definitive hematopoiesis where erythroid, myeloid, and B lymphocyte production occurs. The lineage-specific transcription factors
that serve to regulate this process are in red. Abbreviations: BP: B cell progenitor, CLP: common lymphoid progenitor, CMP: common myeloid progenitor,
EP: erythroid progenitor, Ery: erythrocyte, GMP: granulocyte-monocyte progenitor, Hemangio: hemangioblast, Hetero: heterophil, HSC:
hematopoietic stem cell, Mono: monocyte, TP: T cell progenitor.
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replace the primitive erythrocytes in circulation [23].
Definitive myelopoiesis similarly begins around 3 dpf in
the CHT, as recognized by l-plastin expression [18].
By 54 hpf, some of the HSCs also migrate directly from
the AGM to seed the thymus, the site of lymphopoiesis
[24], developing into ikaros+ lymphoid progenitors [3]. By4 dpf cells in the thymus express rag1, a transcription
factor essential for lymphoid differentiation [25] and
members of the interleukin-2 receptor (IL-2R) family
(Sertori et al., submitted), with mature lymphocytes
found in the thymus by 7 dpf [26]. Between 48 and
96 hpf, HSCs from the AGM and CHT also seed the
marrow of the developing kidney, the ultimate site of
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malian bone marrow [27,28]. These HSCs produce all
hematopoietic lineages, including lymphoid progenitors
that mature to B cells in the kidney from 28 dpf [29] and
additional T cells in the thymus [1]. The thymus and kid-
ney continue to generate hematopoietic cells throughout
adulthood [10].
Zebrafish as a model for leukemia and related disorders
In addition to the strong conservation of key developmen-
tal processes and genes, several other factors make
zebrafish especially amenable to study the disruptions
in hematopoiesis that underpin leukemia and related
disorders. Genes can be easily ablated transiently using
morpholino-mediated gene knockdown [30] or perman-
ently using genome editing approaches, such as transcrip-
tion activator-like effector nucleases (TALENs) [31] or
clustered regularly interspaced short palindromic repeats
(Cas9/CRISPR) [32], or targeting-induced local lesions in
genome (TILLING) [33]. Alternatively, genes can be
overexpressed transiently by introducing mRNA [34]
or DNA [35], or stably through transgenesis, which
extends to a variety of conditional/inducible approaches
[36]. Sophisticated forward genetic screens are feasible in
both zebrafish larvae and adult fish randomly mutated
with chemical or transposon-mediated approaches to
identify new genes involved in specific biological processes,
including disease [37]. The transparent embryos, which
develop externally and therefore are extremely accessible,
provide exquisite opportunities for imaging [38]. These
zebrafish embryo traits are also advantageous for large-
scale drug screening by simple immersion as they are
penetrable to small molecules and drugs [39,40]. These
approaches have yielded new disease models that have in-
creased our knowledge of the oncogenic process and un-
covered novel therapeutics (Table 1).
Acute myeloid leukemia models
The first report using zebrafish as a model for leu-
kemogenesis involved enforced expression of the hu-
man RUNX1-ETO oncogene, the product of the t(8;21)
(q21;q22) translocation found in acute myelogenous
leukemia (AML) [41]. Transient overexpression of this
fusion gene in zebrafish embryos resulted in blood cell
dysplasia, with increased numbers of blast cells, but
reduced numbers of c-myb+ and hbbe3+ cells, along with
circulatory defects [22]. This largely recapitulated the effects
seen in mice [42], providing proof-of-principle evidence
of the usefulness of this model. This study further
showed that knockdown of zebrafish runx1 produced
a similar maturation arrest of blood progenitors that accu-
mulated in the ICM, suggesting a likely dominant-negative
effect of the RUNX1-ETO fusion protein on endogenous
RUNX1 function, providing additional molecular insights[22]. Later, a stable transgenic line was generated that
expressed RUNX1-ETO under the control of the zebra-
fish heat shock-inducible hsp70 promoter. Induction of
RUNX1-ETO elicited a fate change within the erythromye-
loid lineage toward myelopoiesis, evident by upregula-
tion of spi1+ and mpo+ cells at the expense of gata1+
cells. Overexpression of zebrafish scl rescued this pheno-
type, identifying suppression of SCL as an important
mediator of RUNX1-ETO-induced reprogramming, as
could treatment with the histone deacetylase inhibitor Tri-
chostatin A [43]. These observations were consistent
with both the transcriptional changes and therapeutic
sensitivity reported in human AML patients carrying a
RUNX1-ETO translocation [41], underscoring the value
of zebrafish as a leukemic model. In subsequent chemical
suppressor screens performed on this transgenic line, cy-
clooxygenase inhibitors [44] and the benzodiazepine Ro5-
3335 [45] were identified as potential new therapeutics
capable of antagonizing the leukemogenic function of
RUNX1-ETO (Table 2).
The first bona fide zebrafish model of AML was gener-
ated using human MOZ/TIF2, the oncogenic product of
inv(8)(p11q13) observed in AML [46]. Transgenic expres-
sion of MOZ/TIF2 under the control of the zebrafish white
blood cell-specific spi1 promoter led to the development of
overt leukemia, characterized by an accumulation of imma-
ture myeloid cells in the kidney marrow, but decreased
numbers of lymphocyte and precursor cells in the spleen.
However, this occurred after a long latency period of 14
to 26 months, with a low incidence of ~1%, suggest-
ing a role for additional genetic mutations [47].
Gain-of-function mutations in the receptor tyrosine
kinase FLT3, including internal tandem duplications
(FLT3-ITD) and amino acid substitutions in the tyrosine
kinase domain (FLT3-TKD), are commonly found in
AML [48]. Injection of mRNA encoding patient-derived
FLT3-ITD or FLT3-TKD mutants in zebrafish led to
constitutive activation of downstream signaling pathways,
resulting in expansion of myeloid cells reminiscent of
human AML. This was significantly ameliorated by the
tyrosine kinase inhibitor AC220 in the case of FLT3-ITD,
whereas the effects of FLT3-TKD were resistant to this
agent [49].
Mutations in nucleophosmin (NPM1) that result in its
aberrant relocation from nucleus to cytoplasm (termed
NPMc+) represent one of the most common genetic alter-
ations in adult AMLs [50]. Injection of mRNA encoding
human NPMc+, but not NPM1, resulted in perturb-
ation of primitive myelopoiesis, characterized by an
increase in spi1+ myeloid precursors with later expan-
sion of mpo+ and csf1r+ cells, but only in the absence of
p53 [51]. This was consistent with the myeloproliferative
phenotype reported in a transgenic mouse model express-
ing the human NPMc+ mutation [52]. Expression of
Table 1 Zebrafish models of leukemia and other hematological disorders
Disease
model
Gene Expression Latency Penetrance References
AML Hs RUNX1-ETO Ubiquitous Embryonic 32–41% [22]
Ubiquitous - inducible (hs) Embryonic (induced) NS [43,44]
Hs MOZ/TIF2 Progenitor (spi1) 14–26 months 1% [47]
Hs FLT3 Ubiquitous Embryonic NS [49]
Hs NPMc+ Ubiquitous Embryonic NS [51]
Mm Mycn Ubiquitous - inducible (hs) Embryonic (induced) F0: 60% F2: 75% [54]
Dr spi1G242D Endogenous - hypomorph 3 days NS [57]
Dr ddx18 Knockout Embryonic NS [58]
ALL Mm Myc Lymphoid (rag2) F0: 44–52 days F1: 32 days F0: 5–6% F1: 100% [2,34,59]
Lymphoid (rag2) - inducible (cre) 151 days 13% [61]
Lymphoid (rag2) - inducible (cre/hs) T-LBL: 120 days/T-ALL: 261 days T-LBL: 81%/T-ALL: 100% [62,63]
Hs MYC Ubiquitous - inducible (4HT) 4–5 weeks (induced) 100% [66,68]
Dr pten Knockout Embryonic NS [70,71]
Hs NOTCH1ic Lymphoid (rag2) 5 months 44% [73]
Hs ETV6-RUNX1 Ubiquitous 1 year 3% [75]
Dr etv6-jak2a (ALL) Ubiquitous/Progenitor (spi1) Embryonic 30%/50% [78]
MPD Dr jak2aV581F Ubiquitous Embryonic NS [87]
Dr stat5H298R/N714F Ubiquitous Embryonic NS [88]
Dr etv6-jak2a (CML) Ubiquitous/Progenitor (spi1) Embryonic 30%/50% [78,89]
Hs kRASG12D Ubiquitous - inducible (hs + cre) 34 days (induced) 8% [91]
Hs HRASG12V Endothelial (fli1) Embryonic NS [92]
Hs NUP98-HOXA9 Progenitor (spi1) - inducible (hs + cre) 19–23 months 23% [97]
Hs KITD816V Ubiquitous 3–30 months 48–52 % [93]
MDS Dr tet2 Knockout 2 years NS [95]
Dr hspa9b Knockout Embryonic 80% [98]
Hs: Homo sapiens; Mm: Mus musculus; Dr: Danio rerio; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; MPD: myeloproliferative disease;
MDS: myelodysplastic syndrome; NS: not specified; F0: founder; F1: first generation; F2: second generation; hs: heat shock; 4HT: 4-hydroxytamoxifen.
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number of both erythromyeloid precursors in the PBI
and c-myb+/cd41+ HSCs in the ventral wall of the
dorsal aorta, suggesting HSCs as the possible cellular
origin for NPMc+ leukemia [51].
Members of the MYC family of transcription factors
represent some of the most prevalent oncogenes in
cancer, including myeloid malignancies, with MYCN
overexpression frequently reported in AML patients
with a poor prognosis [53]. Transgenic zebrafish
expressing the murine Mycn gene under the control
of the zebrafish hsp70 promoter developed many
aspects of human AML following induction of expres-
sion. This included enhanced cell proliferation and
accumulation of immature blasts, increased myelopoi-
esis and anemia, with immature myeloblasts observed
in the peripheral blood, kidney marrow, and spleen.
Hematopoietic cell fate switch from the erythroid tothe myeloid lineage in these transgenic fish was medi-
ated by upregulation of scl and lmo2, leading to de-
creased expression of gata1 and increased expression
of spi1 and mpo, along with ndrg1, a known MYCN
target involved in granulocytic maturation [54].
Downregulation of SPI1 expression has been con-
sistently associated with AML [55,56]. Zebrafish
carrying a hypomorphic spi1 mutant allele exhibited
overproduction of immature granulocytes in the
CHT by 3 dpf and in the kidney marrow at later
time points, which persisted to 18 months of age.
This was associated with a reduction of lymphoid
cells in kidney marrow and subsequent accumulation
of myeloblasts in the peripheral blood, which closely
mimicked aspects of human myelodysplastic syn-
drome (MDS)/AML. Interestingly, these mutant fish
were sensitive to cytarabine, a chemotherapy agent
used for the treatment of AML, which further
Table 2 List of chemical inhibitors screened in zebrafish models of leukemia
Chemical inhibitors Mechanism Gene References
AML
Trichostatin A Histone deacetylase inhibitor RUNX1-ETO [43]
Nimesulide COX inhibitor RUNX1-ETO [44]
NS-398 COX inhibitor RUNX1-ETO [44]
Indomethacin COX inhibitor RUNX1-ETO [44]
Benzodiazepine RUNX1/CBFβ interactor RUNX1-ETO [45]
AC220 Tyrosine kinase inhibitor FLT3-ITD [49]
T-ALL
Prephenazine PP2A activator MYC [68]
LY294002 PI3K inhibitor pten−/− [71]
AG490 JAK2 inhibitor etv6-jak2a [78]
MPD
TG101209 JAK2 inhibitor jak2aV581F [87]
AG490 JAK2 inhibitor etv6-jak2a [78]
COX: cyclooxygenase; CBFβ: core binding factor β; PP2A: protein phosphatase 2A; PI3K: phosphoinositide 3-kinase.
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testing [57].
Finally, zebrafish have been used in a forward genetic
screen to identify new genes involved in human hematologic
malignancies. This identified a mutation in the ddx18 gene
that resulted in a loss of mature myeloid and erythroid cells
due to increased apoptosis and p53-dependent G1 arrest.
Screening of AML patients identified four non-synonymous
sequence variants of DDX18. One of these showed a domin-
ant negative effect over wild-type ddx18 when expressed in
zebrafish, validating this approach [58].
Acute lymphoblastic leukemia models
The first stable zebrafish leukemic model was generated
by injection of DNA constructs in which sequences en-
coding mouse c-Myc were fused with those for enhanced
green fluorescence protein (EGFP) and placed under the
control of the zebrafish lymphoid-specific rag2 promoter.
This induced T cell acute lymphoblastic leukemia (T-ALL)
with a latency of approximately 7 weeks, with an initial ex-
pansion of EGFP+ cells in the thymus, followed by dissem-
ination of these cells into the kidney marrow, spleen,
muscle, gut, gills, and fins. Gene expression analysis con-
firmed that this was the result of clonal expansion of
transformed pre-T-lymphoblasts. When these cells were
transplanted intraperitoneally into irradiated zebrafish,
they homed back to the thymus before infiltrating other
organs [2], further validating this as a bona fide leukemic
model that has been subsequently utilized for a number of
studies. For example, transplantation of the Myc-induced
T-ALL cells into a syngenic zebrafish line without im-
mune suppression identified a higher frequency of
leukemia-initiating cells in T-ALL than previously
thought, suggesting this may also be the case in humanT-ALL [34]. This T-ALL syngenic zebrafish model was
subsequently used for therapeutic testing, with both cyclo-
phosphamine and vincristine showing efficacy in this
model [59]. Collectively, these studies confirmed the
similarities between zebrafish and mammalian T-ALL
with respect to morphology, genetics and responsiveness
to chemotherapic agents.
A conditional zebrafish transgenic line was generated
from a similar expression construct, but with a loxed
dsRED2 gene inserted upstream of the c-Myc oncogene. In-
duction of transgene expression by injection of mRNA en-
coding Cre-recombinase resulted in the development of
T-ALL with a disease penetrance of ~13% [60]. Further
work in this model demonstrated that enforced expression
of zebrafish bcl2 reduced the radiation sensitivity of these
T-ALL cells [61]. Using a heat shock-inducible Cre-
recombinase, disease penetrance was increased to 81%
[62], with a follow-up study showing that co-expression
of zebrafish bcl2 in this model accelerated the initiation
of T-lymphoblastic lymphoma (T-LBL) but inhibited
progression to T-ALL [63], similar to mouse models
[64,65]. These effects in zebrafish resulted from ele-
vated levels of sphingosine-1-phosphate receptor 1 and
intracellular adhesion molecule 1, which served to in-
crease homotypic cell adhesion and block tumor cell
intravasation [63].
An alternate T-ALL model used human MYC fused to
a modified estrogen receptor, the nuclear transport of
which was controlled by 4-hydroxytamoxifen. Induction
of MYC translocation led to T-ALL, with withdrawal of
4-hydroxytamoxifen resulting in complete tumor regres-
sion in nearly 75% of fish. This model revealed that
MYC suppressed the expression of the tumor suppressor
PTEN, resulting in constitutive activation of the AKT
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zebrafish pten mutations or expression of a constitutively-
active Akt2 rendered tumors MYC-independent [66]. Fur-
ther studies revealed these effects were mediated by the
anti-apoptotic protein BIM [67]. Collectively, these studies
both confirmed the importance of survival signals in ALL
and suggested AKT pathway inhibitors as a new thera-
peutic strategy for T-ALL. A subsequent large-scale drug
screen using this model identified prephenazine, an anti-
cancer drug used to induce apoptosis in T-ALL cells, as
an effective agent. Its effects were shown to be mediated
by protein phosphatase 2A, suggesting that pharmaco-
logical activation of this enzyme may also have therapeutic
potential [68].
The PTEN gene is also frequently mutated in hema-
tological malignancies including T-ALL [69]. Zebrafish
pten−/− mutants showed leukemia-like phenotypes, includ-
ing enhanced proliferation of HSCs within the CHT and
differentiation arrest of committed progenitors across the
erythroid, myeloid, and lymphoid lineages [70,71]. These
phenotypes could be restored by pharmacological inhib-
ition of PI3-K, known to be constitutively activated in the
absence of PTEN, using LY294002 [71].
Activating mutations of NOTCH1 have been ob-
served in nearly 60% of T-ALL patients [72]. Overex-
pression of a T-ALL-derived NOTCH1 intracellular domain
mutant under the control of the zebrafish rag2 promoter
led to the development of a T cell lymphoproliferative
disease. Neoplastic cells invaded tissues and caused a
lethal leukemia when transplanted into irradiated recip-
ients. Crossing of these fish with zebrafish overexpress-
ing the bcl2 gene dramatically accelerated the onset of
leukemia, indicating a strong cooperation between the
NOTCH1 and BCL2 pathways [73].
The ETV6-RUNX1 oncogene, the product of t(1;19)
(q23;p13), is frequently observed in B cell ALL [74]. Ubi-
quitous expression of human ETV6-RUNX1 under the
control of the zebrafish β-actin or Xenopus ef-1 pro-
moters resulted in expansion of lymphoid progenitors
that resulted in oligoclonal B cell ALL at a frequency
of ~3% after a latency period of 8–12 months. These fish
showed a dramatic increase in total leukocyte count with
more than 90% lymphoblasts observed in blood smears,
with enlarged kidneys, the marrow of which were almost
completely replaced with lymphoblasts, and dissemin-
ation of these cells into the brain, liver, muscle, and
ovary, phenotypes reminiscent of childhood pre-B ALL
in humans [74]. Lymphoblasts isolated from kidney mar-
row of these fish caused similar phenotypes in irradiated
recipients between 6 and 9 weeks post transplantation,
confirming the leukemic nature of these cells. This study
identified pro-B precursors as the cellular target of
ETV6-RUNX1 fusion, along with downregulation of the
ETV6 tumor suppressor gene and deregulation of apoptoticgenes, including an altered BCL2:BAX ratio, as po-
tential molecular mediators of ETV6-RUNX1-induced
leukemogenesis [75].
Other studies have shown that zebrafish gene ortholo-
gues can also recapitulate human oncogenes, further dem-
onstrating conserved functionality across the two species.
Alternative ETV6-JAK2 fusions have been identified in
both ALL and atypical chronic myelogenous leukemia
(CML), that lead to constitutive activation of the JAK2
tyrosine kinase and downstream pathways [76,77]. A fu-
sion was constructed from zebrafish etv6 and jak2a genes
corresponding to a human T-ALL-derived ETV6-JAK2.
Transient expression of this etv6-jak2a fusion using either
the zebrafish spi1 promoter or the ubiquitous cytomegalo-
virus promoter caused specific disruption of lymphoid
cells, with an increased number of rag1+ cells resulting in
a fatal lymphoproliferative disorder [78]. The ETV6 gene
has also been identified as a tumor-suppressor gene in
lymphoid and other malignancies, with its function ab-
lated by both epigenetic and genetic disruption, including
the acquisition of truncating mutations [79]. Recent stud-
ies have shown that knockdown of zebrafish etv6 resulted
in a range of hematopoietic effects, including enhanced
lymphopoiesis [80], while transient expression of trun-
cated forms of the etv6 protein exerted similar effects,
acting dominantly over the wild-type etv6 protein [81].
To identify other genetic lesions underlying T-ALL, a
phenotype-driven forward genetic screen has been per-
formed using chemical mutagenesis of transgenic zebra-
fish expressing EGFP+ in T lymphocytes. Several mutant
lines were identified that recapitulated human T-ALL
and T-LBL in both molecular and clinical features [82].
Iterative allo-transplantation of the T-ALL cells, select-
ing for aggressive disease that models relapsed human
T-ALL, yielded leukemic clones that preserved the ori-
ginal genetic aberration in 55% of cases. However, these
cells also acquired additional genetic aberrations that
might be responsible for their enhanced malignant be-
havior. More importantly, over 50% of these genes were
shared in relapsed human T-ALL samples, reiterating
the similar molecular processes governing zebrafish and
human hematopoietic malignancies [83].
Myeloproliferative disorder models
Deregulation of the JAK/STAT signaling pathway is asso-
ciated with a variety of myeloproliferative disorders
(MPDs) [84,85]. For example, the somatic activating
JAK2V617F mutation is commonly observed in polycythemia
vera and other myeloproliferative disorders [86]. Injection of
mRNA encoding the equivalent zebrafish jak2aV581F mutant
resulted in enhanced erythropoiesis, with a significant
increase in gata1+ precursors, concomitant with increased
phosphorylation of the downstream stat5.1 transcription fac-
tor. Moreover, the effects of jak2aV581F could be significantly
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clinical situation, as well as knockdown of stat5.1, confirming
the importance of this downstream pathway [87]. By corol-
lary, transient expression of a constitutively-active zebrafish
stat5.1H298R/N714F mutant led to the expansion of early and
late myeloid cells, erythrocytes, and lymphoid cells
[88]. An ETV6-JAK2 fusion gene has also been identi-
fied in atypical CML [76]. Expression of the corre-
sponding zebrafish etv6-jak2a fusion gene using either
the spi1 or CMV promoter resulted in progenitor hyper-
proliferation, with increased numbers of immature mye-
loid and erythroid cells, perturbed mature myeloid cells
and anemia, with the lymphoid lineage largely unaffected
[89]. This contrasted with the phenotypes observed with
the ALL-derived etv6-jak2a fusion, with the functional dif-
ferences correlating with increased activation of the down-
stream STAT transcription factors by the atypical CML-
derived etv6-jak2a fusion that also showed enhanced
sensitivity to JAK2 inhibitors [78].
Activating mutations in RAS genes have been implicated
in a number of human proliferative conditions, including
the MPD juvenile myelomonocytic leukemia [90]. The first
stable model of MPD-utilized heat shock-inducible Cre/
Lox-mediated expression of human kRASG12D from the
zebrafish β-actin promoter. Whole animal heat shock induc-
tion resulted in high tumor incidence with short latency, but
associated with significant juvenile lethality and a propensity
to develop other disorders, like rhabdomyosarcoma, intes-
tinal hyperplasia, and malignant peripheral nerve sheath
tumor. In contrast, ex vivo heat shock of kidney marrow
cells specifically elicited a MPD when transplanted into sub-
lethally irradiated recipient fish [91]. Expression of the
HRASG12V oncogene from the zebrafish fli1 promoter also
recapitulated several pathologic aspects of MPD, including
defective definitive hematopoiesis, with enhanced prolifera-
tion and infiltration of leukocytes into the CHT and kidney
marrow. However, no perturbation of the lymphoid lineage
was observed, highlighting the lineage-specific function
of this oncogene. Expression of HRASG12V was also
shown to downregulate NOTCH signaling, which con-
tributed to the proliferation of erythromyeloid progeni-
tors and disease pathogenesis [92].
Activating mutations in the receptor tyrosine kinase
encoding c-KIT gene have been observed in systemic
mastocytosis (SM), a rare MPD characterized by the in-
filtration of the clonally derived mast cells into a variety
of different tissues including bone marrow [90]. Trans-
genic expression of the SM-derived KITD816V mutant
under the control of the zebrafish β-actin promoter re-
capitulated features of aggressive SM, with infiltration of
mast cells into the kidney marrow, associated with ele-
vated expression of mast cell proteases, decreased epcam
expression, and defects in cell-cycle progression, with
significantly increased apoptosis [93].Myelodysplastic syndrome models
Mutation of the Ten-Eleven Translocation 2 (TET2) gene
has been observed in MDS [94]. A tet2−/− zebrafish line gen-
erated through genome editing demonstrated normal em-
bryonic hematopoiesis, but developed a pre-myelodysplasia
at 11 months of age. This culminated in true MDS at
24 months, characterized by increased progenitor and
myelomonocytic cell numbers, and decreased erythro-
cyte cell numbers within the kidney marrow [95].
The NUP98-HOXA9 oncogene, the product of t(7;11)
(p15;p15), has been observed in MDS, CML blast crisis,
and AML [96]. Conditional expression of the human
NUP98-HOXA9 oncogene under the control of the zebra-
fish spi1 promoter was achieved using a Cre/lox-heat
shock induction strategy. Heat shock-induced expression
of NUP98-HOXA9 perturbed hematopoiesis, with en-
hanced spi1+ myeloid precursors at the expense of gata1+
erythroid precursors. However, there was also disruption
of myeloid differentiation, since mature lcp+, lyz+, and
mpo+ myeloid cells were not expanded as much as the
myeloid precursors. About 23% of the transgenic fish
developed myeloproliferative neoplasms between 19 and
23 months, none of which progressed to AML [97].
Recently, the zebrafish crimsonless (crs) mutant was
identified in a forward genetic screen that exhibited
phenotypes consistent with MDS, including multiline-
age cytopenia, including decreased hbbe3+ and mpo+
cells, disrupted gata1+ precursors, and cell dysplasia.
The causal mutation in crs was identified in hspa9b, en-
coding a conserved mitochondrial matrix chaperone, with
the loss-of-function hspa9bG492E mutation disrupting the
substrate-binding domain of the protein. This resulted in
perturbed mitochondrial function with increased produc-
tion of reactive oxygen species (ROS) triggering oxidative
stress and apoptosis of blood cells, leading to MDS [98].
Conclusions
Zebrafish has emerged as a robust model for human
leukemia and related disorders, including AML, ALL,
MPD, and MDS. They have proven susceptible to a range
of clinically relevant mutations, including those modeled
on zebrafish genes, when expressed ubiquitously or in a
lineage-specific manner. Alternatively, genetic screening
has identified novel genes involved in these diseases. These
models have provided unique insights into molecular and
cellular aspects of disease etiology, as well as proving ef-
fective for therapeutic screening. However, there remains
considerable scope for even greater use of this model. The
transparency of this organism combined with exquisite
transgenic and other fluorescent labeling approaches pro-
vides endless opportunities for high resolution in vivo
imaging of tumor cell proliferation, dissemination, and
interactions with the vasculature and other tissues [99].
The development of highly efficient genome editing
Rasighaemi et al. Journal of Hematology & Oncology  (2015) 8:29 Page 8 of 10approaches expands the potential to interrogate oncogenic
and tumor-suppressor pathways and their interactions. In
addition, a variety of xenotransplantation approaches are
being developed [100], with the generation of immunode-
ficient and other useful zebrafish strains further enhancing
the possibilities. These collectively provide increasingly
advanced platforms for pre-clinical therapeutic develop-
ment, including at the individual patient level, which will
underpin advances in individualized medicine.
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